Association between tumor necrosis factor-α (TNF-α) promoter −308 G/A and response to TNF-α blockers in rheumatoid arthritis: a meta-analysis

REFERENCES

• Harris ED Jr. Rheumatoid arthritis. Pathophysiology and impli-cations for therapy. N Engl J Med. 1990;1990(322):1277–89.
   Google Scholar
• Brennan FM, Maini RN, Feldmann M. TNF-a: a pivotal role in rheumatoid arthritis. Br J Rheumatol. 1992;31:293–8.
   Google Scholar
• Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344:907–16.
   PubMed Web of Science ®Google Scholar
• Coenen MJ, Toonen EJ, Scheffer H, Radstake TR, Banera P, Franke B. Pharmacogenetics of anti-TNF treatment in patients with rheumatoid arthritis. Pharmacogenomics. 2007;8:761–73.
   PubMed Web of Science ®Google Scholar
• Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breed-veld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med. 2000;343:1594–602.
   Google Scholar
• Weyand C, Goronzy J. The molecular basis of rheumatoid arthritis. J Mol Med. 1997;75:772–85.
   PubMed Web of Science ®Google Scholar
• Allen RD. Polymorphism of the human TNF-alpha promoter-random variation or functional diversity? Mol Immunol. 1999;36: 1017–27.
   Google Scholar
• Lee YH, Rho YH, Choi SJ, Ji JD, Song GG. Association of TNF-alpha -308G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: a meta-analysis. Rheumatol Int. 2006;27: 157–61.
   Google Scholar
• O'Rielly DD, Roslin NM, Beyene J, Pope A, Rahman P. TNF-alpha-308 G/A polymorphism and responsiveness to TNF-alpha blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis. Pharmacogenomics J. 2009;9:161–7.
   PubMed Web of Science ®Google Scholar
• Pavy S, Toone EJM, Miceli-Richard C. Tumour necrosis factor a-308G - A polymorphism is not associated with response to TNF-a blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis. Ann Rheum Dis. 2010;69(6): 1022–8.
   Google Scholar
• Lee YH, Ji JD, Bae SC, Song GG. Associations between tumor necrosis factor-a (TNF-a) -308 and -238 G/A polymorphisms and shared epitope status and responsiveness to TNF-a blockers in rheumatoid arthritis: a metaanalysis update. J Rheumatol. 2010;37(4):740–6.
   PubMed Web of Science ®Google Scholar
• Mugnier B, Balandraud N, Darque A, Roudier C, Roudier J, Reviron D. Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum. 2003;48:1849–52.
   PubMed Web of Science ®Google Scholar
• Padyukov L, Lampa J, Heimburger M, Emestam S, Cederholm T, Lundkvist I, et al. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis. 2003;62:526–9.
   PubMed Web of Science ®Google Scholar
• Balog A, Gal J, Gyulai Z, Zsilak S, Mandi Y. Tumour necrosis factor-alpha and heat-shock protein 70–2 gene polymorphisms in a family with rheumatoid arthritis. Acta Microbiol Immunol Hung. 2004;51: 263–9.
   Google Scholar
• Criswell LA, Lum RF, Turner KN, Woehl B, Zhu Y, Wang J, et al. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheu-matoid arthritis with methotrexate or etanercept. Arthritis Rheum. 2004;50:2750–6.
   PubMed Web of Science ®Google Scholar
• Cuchacovich M, Ferreira L, Aliste M, Soto L, Cuenca J, Cruzat A, et al. Tumour necrosis factor-alpha (TNF-alpha) levels and influence of -308 TNF-alpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis. Scand J Rheumatol. 2004;33:228–32.
   PubMed Web of Science ®Google Scholar
• Fonseca JE, Carvalho T, Cruz M, Nero P, Sobral M, Mourao AF, et al. Polymorphism at position -308 of the tumour necrosis factor alpha gene and rheumatoid arthritis pharmacogenetics. Ann Rheum Dis. 2005;64:793–4.
   PubMed Web of Science ®Google Scholar
• Kang CP, Lee KW, Yoo DH, Kang C, Bae SC. The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheu-matoid arthritis. Rheumatology (Oxford). 2005;44: 547–52.
   Google Scholar
• Cuchacovich M, Soto L, Edwardes M, Gutierrez M, Llanos C, Pacheco D, et al. Tumour necrosis factor (TNF) a-308 GIG promoter polymorphism and TNFa levels correlate with a better response to adalimumab inpatients with rheumatoid arthritis. Scand J Rheumatol. 2006;35:435–40.
   PubMed Web of Science ®Google Scholar
• Seitz M, Wirthmuller U, Moller B, Villiger PM. The-308 tumour necrosis factor-a gene polymorphism predicts therapeutic response to TNF-blockers in rheumatoid arthritis and spondyl-oarthritis patients. Rheumatology. 2007;46:93–6.
   PubMed Web of Science ®Google Scholar
• Guis S, Balandraud N, Bouvenot J, Auger I, Toussirot E, Wendling D, et al. Influence of-308 A/G polymorphism in the tumor necrosis factor a gene on etanercept treatment in rheu-matoid arthritis. Arthritis Rheum. 2007;57:1426–30.
   PubMed Web of Science ®Google Scholar
• Chatzikyriakidou A, Georgiou I, Voulgari PV, Venetsanopoulou AT, Drosos AA. Combined tumour necrosis factor-alpha and tumour necrosis factor receptor genotypes could predict rheu-matoid arthritis patients' response to anti-TNF-alpha therapy and explain controversies of studies based on a single polymorphism. Rheumatology (Oxford). 2007;46:1034–5.
   Google Scholar
• Marotte H, Arnaud B, Diasparra J, Zrioual S, Miossec P. Asso-ciation between the level of circulating bioactive tumor necrosis factor a and the tumor necrosis factor a gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor a inhibitor. Arthritis Rheum. 2008;58: 1258–63.
   Google Scholar
• Maxwell JR, Potter C, Hyrich KL, BRAGGSS, Barton A, Worthington J, et al. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum Mol Genet. 2008;17: 3532–3538.
   PubMed Web of Science ®Google Scholar
• Miceli-Richard C, Comets E, Verstuyft C, Tamouza R, Loiseau P, Ravaud P, et al. A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis. Ann Rheum Dis. 2008;67:478–84.
   Google Scholar
• Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology.Preliminary definition of improvement in rheumatoid arthritis. Arthitis Rheum.1995;38:727–735.
   PubMed Web of Science ®Google Scholar
• Berol L, Rennie D. The Cochrane collaboration. Preparing, maintaining, and disseminating systematic reviews of the effects of health care. JAMA. 1995;274:1935–8.
   Google Scholar
• Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epi-demiology: a proposal for reporting. Meta-analysis Of Observa-tional Studies in Epidemiology (MOOSE) group. JAMA. 2000; 283(15):2008–12.
   Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315–24.
   PubMed Web of Science ®Google Scholar
• Vassalfi P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol. 1992;10:411–52.
   PubMed Web of Science ®Google Scholar
• Louis E, Franchimont D, Piron A, Gevaert Y, Schaaf-Lafontaine N, Roland S, et al. Tumour necrosis factor (TNF) gene poly-morphism influences TNF-alpha production in lipopoly-saccha-ride (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol. 1998;113:401–6.
   Google Scholar
• Brinkman BM, Huizinga TW, Kurban SS, van der Velde EA, Schreuder GM, Hazes JM, et al. Tumour necrosis factor alpha gene polymorphisms in rheumatoid arthritis: association with susceptibility to, or severity of, disease? Br J Rheumatol. 1997;36: 516–21.
   Google Scholar